These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus. Nishimura K; Harigai M; Omori M; Sato E; Hara M Psychoneuroendocrinology; 2008 Apr; 33(3):395-403. PubMed ID: 18261856 [TBL] [Abstract][Full Text] [Related]
3. New-onset psychiatric disorders after corticosteroid therapy in systemic lupus erythematosus: an observational case-series study. Nishimura K; Omori M; Sato E; Katsumata Y; Gono T; Kawaguchi Y; Harigai M; Yamanaka H; Ishigooka J J Neurol; 2014 Nov; 261(11):2150-8. PubMed ID: 25142268 [TBL] [Abstract][Full Text] [Related]
4. Detailed assessment and risk factor analysis of corticosteroid-induced psychiatric disorders in pediatric, adolescent, and young adult patients undergoing induction or consolidation therapy for hematologic malignancy. Staub Y; Suga Y; Ikawa Y; Tsubouchi K; Hashimoto M; Kawagishi A; Shimada T; Sai Y; Nishimura K; Matsushita R J Oncol Pharm Pract; 2020 Jul; 26(5):1041-1051. PubMed ID: 31635550 [TBL] [Abstract][Full Text] [Related]
5. Effect of high-dose intravenous methylprednisolone pulse (IVMP) therapy in the survival of patients with anti-melanoma differentiation-associated gene 5-related rapidly progressive interstitial lung disease: a retrospective analysis. Fan L; Li Y; Lyu W; Xu Q; Gao Y; Qiu X; Cai H; Dai J Clin Rheumatol; 2024 Mar; 43(3):1135-1143. PubMed ID: 38289569 [TBL] [Abstract][Full Text] [Related]
7. A comparison of intravenous methylprednisolone and hydrocortisone for the treatment of acute inflammatory bowel disease. Schauer C; Avery V; Seleq S; Garg P; Wang MTM; Chieng M; Rowan C; Sekra A; Lane M; Walmsley R J Gastroenterol Hepatol; 2021 Oct; 36(10):2762-2768. PubMed ID: 33939853 [TBL] [Abstract][Full Text] [Related]
8. Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit. Yaqoob H; Greenberg D; Hwang F; Lee C; Vernik D; Manglani R; Wang Z; Murad MH; Chandy D; Epelbaum O J Med Virol; 2022 Jan; 94(1):349-356. PubMed ID: 34542192 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of i.v. methylprednisolone pulse therapy for vitiligo: A retrospective study of 58 therapy experiences for 33 vitiligo patients. Wada-Irimada M; Tsuchiyama K; Sasaki R; Hatchome N; Watabe A; Kimura Y; Yamasaki K; Aiba S J Dermatol; 2021 Jul; 48(7):1090-1093. PubMed ID: 33768620 [TBL] [Abstract][Full Text] [Related]
10. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370 [TBL] [Abstract][Full Text] [Related]
11. Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis. Hoff LS; de Souza FHC; Miossi R; Shinjo SK Rheumatology (Oxford); 2022 Apr; 61(4):1579-1588. PubMed ID: 34302454 [TBL] [Abstract][Full Text] [Related]
12. [Effects of intravenous methylprednisolone pulse therapy on optic neuritis associated with AQP4 antibody seropositive neuromyelitis optica]. Guo ST; Li Z; Jiang LB; Wu RH; Peng JT; Wang JW; Wei WB Zhonghua Yan Ke Za Zhi; 2019 Mar; 55(3):180-185. PubMed ID: 30841684 [No Abstract] [Full Text] [Related]
13. One-year recurrence rate of Graves ophthalmopathy presenting as diplopia in the primary position after varied doses of intravenous methylprednisolone followed by oral prednisolone with dosing based on the magnetic resonance imaging findings. Ueki S; Hasegawa Y; Hatase T; Kiyokawa M; Fukuchi T Jpn J Ophthalmol; 2023 Jan; 67(1):91-96. PubMed ID: 36301447 [TBL] [Abstract][Full Text] [Related]
14. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Zivadinov R; Rudick RA; De Masi R; Nasuelli D; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M Neurology; 2001 Oct; 57(7):1239-47. PubMed ID: 11591843 [TBL] [Abstract][Full Text] [Related]
15. Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. Lang B; Dooley J J Pediatr; 1996 Mar; 128(3):429-32. PubMed ID: 8774518 [TBL] [Abstract][Full Text] [Related]
16. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Ogata S; Ogihara Y; Honda T; Kon S; Akiyama K; Ishii M Pediatrics; 2012 Jan; 129(1):e17-23. PubMed ID: 22144699 [TBL] [Abstract][Full Text] [Related]
17. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease. Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091 [TBL] [Abstract][Full Text] [Related]
18. Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Cornblath WT; Eggenberger ER Ophthalmology; 1997 May; 104(5):854-8. PubMed ID: 9160034 [TBL] [Abstract][Full Text] [Related]
19. Treatment of severe idiopathic orbital inflammation with intravenous methylprednisolone. Bijlsma WR; Paridaens D; Kalmann R Br J Ophthalmol; 2011 Aug; 95(8):1068-71. PubMed ID: 21349945 [TBL] [Abstract][Full Text] [Related]
20. Factors influencing intravenous methylprednisolone pulse therapy in Chinese patients with isolated optic neuritis associated with AQP4 antibody-seropositive neuromyelitis optica. Guo S; Jiang H; Jiang L; Peng J; Liu H; Wang J; Wei W Sci Rep; 2021 Nov; 11(1):22229. PubMed ID: 34782653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]